Sign In
Buy SNN
$29.36
-0.120 (-0.407%)
At Close: Jun 02, 2026
We are having constructive engagement with activist shareholders, says Smith & Nephew CEO
11:00am, Tuesday, 25'th Feb 2025
Deepak Nath, CEO of Smith & Nephew discusses spin offs, navigating the China market, and the medical tech firm's full-year earnings for 2024.
Smith & Nephew sees turnaround plan kicking in as profit grows
02:41am, Tuesday, 25'th Feb 2025
Smith & Nephew PLC has said 2025 should show its transformation plan kicking in despite ongoing woes in China after improving trading over the last year. Revenue climbed 4.7% to US$5.8 billion in the
UK's Smith+Nephew beats annual profit expectations
02:09am, Tuesday, 25'th Feb 2025
Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset
Smith & Nephew has to impress in results after ringing warning bell
07:18am, Friday, 21'st Feb 2025
Smith & Nephew PLC has left itself with the mounting task of having to give investors something to cheer about after ringing the warning bell last time out. Ahead of full-year figures on Tuesday, 25 F
Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand
06:00pm, Sunday, 16'th Feb 2025
First in market to o ffe r A djustable T ensioning T echnology * for i nsertional A chilles r econstruction and l ateral a nkle i nstability r epair
Smith+Nephew and UFC to host first-of-its-kind medical education course for treatment of injuries in combat sport athletes
10:00am, Monday, 03'rd Feb 2025
Healthcare professionals are invited to register for the livestream option as a courtesy here
Smith & Nephew Getting No Credit For Self-Improvement Efforts
08:37am, Wednesday, 29'th Jan 2025
Smith & Nephew's stock has underperformed, driven by ongoing market share losses in hip and knee markets and pricing pressures in China, raising concerns about its ongoing multiyear restructuring prog
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence
Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally
SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA
10:06am, Friday, 20'th Dec 2024
Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty.
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty
10:00am, Thursday, 19'th Dec 2024
Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today annou
SNN Stock Might Rise Following FDA Nod for AETOS Stemless
08:45am, Tuesday, 17'th Dec 2024
Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty.
Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty
10:00am, Monday, 16'th Dec 2024
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total
Smith & Nephew has the potential to pop next year, says leading US investment bank
06:44am, Tuesday, 03'rd Dec 2024
JP Morgan has doubled down on its "overweight" recommendation for Smith & Nephew PLC (LSE:SN) with its analysts deeming the medical device company undervalued, trading near trough levels, with potent
Big investors call for break-up of Smith & Nephew, FT reports
12:24am, Thursday, 14'th Nov 2024
Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.
